Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr;120(4):418-422.
doi: 10.1007/s00347-022-01660-0. Epub 2022 May 31.

[Belantamab mafodotin-associated keratopathy-A common and treatment-affecting side effect]

[Article in German]
Victor A Augustin  1 , Louise Blöck  2 , Ute Hegenbart  3 , Gerd U Auffarth  2 , Ramin Khoramnia  2
Affiliations

[Belantamab mafodotin-associated keratopathy-A common and treatment-affecting side effect]

[Article in German]
Victor A Augustin et al. Ophthalmologie. 2023 Apr.
No abstract available

PubMed Disclaimer

References

Literatur

    1. Raizman MB et al (2017) Drug-induced corneal epithelial changes. Surv Ophthalmol 62(3):286–301 - DOI - PubMed
    1. Farooq AV et al (2020) Corneal epithelial findings in patients with multiple myeloma treated with antibody-drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM‑2 study. Ophthalmol Ther 9(4):889–911 - DOI - PubMed - PMC
    1. Wahab A et al (2021) Ocular toxicity of belantamab mafodotin, an oncological perspective of management in relapsed and refractory multiple myeloma. Front Oncol 11:678634 - DOI - PubMed - PMC
    1. Lonial S et al (2021) Management of belantamab mafodotin-associated corneal events in patients with relapsed of refractory multiple myeloma (RRMM). Blood Cancer J 11(5):103 - DOI - PubMed - PMC
    1. Chuang K, Pineda R, Liu S (2022) Belantamab mafodotin associated corneal microcyst-like epithelial changes. Am J Ophthalmol Case Rep 25:101392 - DOI - PubMed - PMC

Publication types

MeSH terms

Substances

LinkOut - more resources